Sol-Gel Technologies Ltd.

SLGL

Healthcare Biotechnology

Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.

Revenue
−96.6%
EPS
−127.1%
Free cash flow
−8.76%

Quarter to June 2026, against a year earlier

61.01 2.00 −3.17%
Market cap
$199.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
6/9
Net debt / EBITDA
3.2×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
135.10 12.17 6.06 4.28
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(29.34) 697.97 364.60 135.58
P/B ratio
5.04 4.37 5.15 3.12
EV/Sales
144.80 12.85 8.19 6.63
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(12.22) (11.51) (7.70) (4.29)
Current Ratio
10.37 8.84 4.37 5.15
Net Debt/EBITDA
11.52 13.70 7.04 3.31
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(7.61%) (0.43%) (5.29%) (11.18%)
Free Cash Flow Yield
(8.77%) (9.17%) (17.55%) (36.06%)
Free Cash Flow per Share
(2.53) 0.00 0.12 0.00
Book value per Share
14.70 18.12 8.19 9.34
Free Cash Flow
(8.29) — 0.33 —
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates